Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study.
Saved in:
| Title: | Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study. |
|---|---|
| Authors: | Hartung HP; Department of Neurology, Universitätsklinikum Düsseldorf (UKD) and Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany/Center for Neurology and Neuropsychiatry, LVR-Klinikum Düsseldorf, Medical Faculty, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany/Brain and Mind Centre, The University of Sydney, Sydney, NSW, Australia/Department of Neurology, Medical University of Vienna, Vienna, Austria., Derfuss T; Department of Neurology, Universitätsspital Basel, Basel, Switzerland., Cree BA; Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA., Sormani MP; Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy/Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Ospedale Policlinico San Martino, Genova, Italy., Selmaj K; Department of Neurology, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland/Department of Neurology, Medical Academy of Łódź, Łódź, Poland., Stutters J; Nuclear Magnetic Resonance (NMR) Research Unit, Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London, London, UK., Prados F; Nuclear Magnetic Resonance (NMR) Research Unit, Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London, London, UK/Centre for Medical Image Computing (CMIC), Department of Medical Physics and Biomedical Engineering, University College London, London, UK; Universitat Oberta de Catalunya, Barcelona, Spain., MacManus D; Nuclear Magnetic Resonance (NMR) Research Unit, Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London, London, UK., Schneble HM; Centre for Medical Image Computing (CMIC), Department of Medical Physics and Biomedical Engineering, University College London, London, UK., Lambert E; Institut de Recherches Internationales Servier, Suresnes, France., Porchet H; GeNeuro SA, Geneva, Switzerland/Department of Pharmacology, University of Pretoria, Pretoria, South Africa., Glanzman R; GeNeuro SA, Geneva, Switzerland., Warne D; GeNeuro SA, Geneva, Switzerland., Curtin F; GeNeuro SA, Geneva, Switzerland; Clinical Pharmacology and Toxicology Division, Geneva University Hospitals, Geneva, Switzerland., Kornmann G; GeNeuro SA, Geneva, Switzerland., Buffet B; GeNeuro SA, Geneva, Switzerland., Kremer D; Department of Neurology, Universitätsklinikum Düsseldorf (UKD) and Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany/Center for Neurology and Neuropsychiatry, LVR-Klinikum Düsseldorf, Medical Faculty, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany., Küry P; Department of Neurology, Universitätsklinikum Düsseldorf (UKD) and Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany/Center for Neurology and Neuropsychiatry, LVR-Klinikum Düsseldorf, Medical Faculty, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany., Leppert D; Brain and Mind Centre, The University of Sydney, Sydney, NSW, Australia/GeNeuro SA, Geneva, Switzerland., Rückle T; GeNeuro SA, Geneva, Switzerland., Barkhof F; Nuclear Magnetic Resonance (NMR) Research Unit, Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, University College London, London, UK/Centre for Medical Image Computing (CMIC), Department of Medical Physics and Biomedical Engineering, University College London, London, UK/Department of Radiology and Nuclear Medicine, VU University Medical Center Amsterdam, Amsterdam, The Netherlands. |
| Source: | Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2022 Mar; Vol. 28 (3), pp. 429-440. Date of Electronic Publication: 2021 Jul 09. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: SAGE Publications Country of Publication: England NLM ID: 9509185 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-0970 (Electronic) Linking ISSN: 13524585 NLM ISO Abbreviation: Mult Scler Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
